Loading clinical trials...
Loading clinical trials...
A Multicentre, Double-blind, Randomised, Parallel-group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
The purpose of this study is to determine whether treatment with D9421-C for 8 weeks in Japanese patients with mild to moderate active Crohn's disease will improve their symptoms of Crohn's disease and quality of life.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Research Site
Nagoya, Aichi-ken, Japan
Research Site
Sakura, Chiba, Japan
Research Site
Chikushino-shi, Fukuoka, Japan
Research Site
Fukuoka, Fukuoka, Japan
Research Site
Kurume, Fukuoka, Japan
Research Site
Hashima-gun, Gifu, Japan
Research Site
Fukuyama, Hiroshima, Japan
Research Site
Hiroshima, Hiroshima, Japan
Research Site
Asahikawa, Hokkaido, Japan
Research Site
Sapporo, Hokkaido, Japan
Start Date
October 1, 2006
Primary Completion Date
March 1, 2008
Completion Date
March 1, 2008
Last Updated
July 12, 2012
75
ACTUAL participants
D9421-C, 9mg
DRUG
D9421-C, 15mg
DRUG
Placebo
DRUG
Lead Sponsor
AstraZeneca
NCT06226883
NCT07184931
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06918808